Waverly Advisors’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$19.7M Buy
122,057
+2,824
+2% +$471K 0.11% 174
2026
Q2
$22.6M Sell
119,233
-103
-0.1% -$19.4K 0.13% 154
2026
Q1
$23.4M Buy
119,336
+426
+0.4% +$82.1K 0.18% 119
2025
Q4
$21.9M Buy
118,910
+517
+0.4% +$90.7K 0.18% 114
2025
Q3
$18.2M Buy
118,393
+3,276
+3% +$496K 0.18% 110
2025
Q2
$16.1M Buy
115,117
+3,072
+3% +$431K 0.18% 116
2025
Q1
$16.5M Buy
112,045
+99,967
+828% +$14.5M 0.2% 106
2024
Q4
$1.58M Buy
12,078
+7,941
+192% +$1.11M 0.02% 433
2024
Q3
$645K Sell
4,137
-199
-5% -$32.1K 0.01% 533
2024
Q2
$676K Buy
4,336
+355
+9% +$53.4K 0.01% 509
2024
Q1
$539K Buy
3,981
+1,183
+42% +$157K 0.01% 465
2023
Q4
$377K Sell
2,798
-35
-1% -$4.55K 0.01% 335
2023
Q3
$384K Buy
2,833
+375
+15% +$51.2K 0.02% 291
2023
Q2
$352K Buy
+2,458
New +$362K 0.02% 278
2014
Q4
– Sell
-122
Closed -$9K – 436
2014
Q3
$9K Hold
122
– – ﹤0.01% 498
2014
Q2
$9K Sell
122
-99
-45% -$7.16K ﹤0.01% 465
2014
Q1
$14K Hold
221
– – 0.01% 369
2013
Q4
$13K Buy
+221
New +$12K ﹤0.01% 518

Other funds holding AZN

Waverly Advisors's AZN Position: Q3 2026 in Review

Waverly Advisors increased its AstraZeneca (AZN) stake by 2.4% in Q3 2026, buying an estimated $471K and bringing the position to 122,057 shares worth $19.7M. The position accounts for 0.11% of the portfolio, ranked #174.

Waverly Advisors first reported a position in AZN in Q4 2013 and has held it in 18 quarters since. The position peaked at $23.4M in Q1 2026. 1,441 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Waverly Advisors held 122,057 shares of AstraZeneca worth $19.7M as of Q3 2026.
  • Waverly Advisors bought 2,824 AstraZeneca shares in Q3 2026, an estimated $471K.
  • AstraZeneca made up 0.11% of Waverly Advisors's portfolio in Q3 2026, its #174 holding.
  • Waverly Advisors first reported a position in AstraZeneca in Q4 2013 and has held it in 18 quarters since.
  • Waverly Advisors's AstraZeneca position peaked at $23.4M in Q1 2026.
  • 1,441 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Waverly Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.